Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More Information

Total Page:16

File Type:pdf, Size:1020Kb

Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More Information Cambridge University Press 978-0-521-86781-8 - Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More information Index Abdominal distension in lung elastance oxygen toxicity 270 incidence data 240 345, 346 patient assessment 118, 115–119, 120 laryngeal injuries 248, 247–248 Abdominal paradox 27 recruitment manoeuvres 118–119, left ventricular performance 273 N-Acetylcysteine 79–80, 81, 357, 358 131, 219 lorazepam 165 Acinetobacter baumanii, SDD for 260 trials (See ARDS net trials) lung injury, ventilator-associated (See Acute hypoxaemic respiratory failure ventilation management Lung injury, defined 115 HFOV 127–131, 305–306 ventilator-associated) Acute lung injury (ALI) IRV 125–126 maxillary sinusitis/middle ear blast injuries 212 liquid 228 effusions 246–247 hypoxaemia, PEEP management of modes 215–216 midazolam 165 124–125 overview 214 nasopharyngeal airways 243–245, infants/children 300–301 principles 214–215, 216 246–247 liquid ventilation 228 Acute respiratory failure (ARF) nasotracheal intubation 315 patient assessment 118, 115–119, clinical presentation 29 neurological function 277, 276–277, 120, 197 mechanisms of 24 278, 280 recruitment manoeuvres 131, 219 NIV 43, 49–50 (See also Non-invasive NMBAs 171, 176–177, 276–280 ventilation management ventilation (NIV)) NSAIDs 181 HFV 149–150 overview 24, 22–24, 25, 142 opioid agonists 180 IRV 125–126 Adaptive support ventilation® 113, 361 opioids 276–280 modes 215–216 Adrenaline 81 overview 21, 239, 241 overview 214 Adrenergic receptor antagonists 349, oxygen toxicity 270, 269–270 principles 214–215 348–349, 350 paralysis 176–177 Acute necrotizing myopathy 205, 205, Adverse effects/complications PEEP 125, 126, 198 356 analgesia 276–280 perforations 243 Acute quadriplegic myopathy artificial airway management 58, pharyngo-laryngeal dysfunction 247 syndrome (AQMS) 177 62–63, 72–73 pneumothorax 241–242 Acute renal failure 156 aspiration 242–243, 247, 266 propofol 165–166, 276–280 Acute respiratory distress syndrome aspiration pneumonitis 242–243, pulmonary vascular resistance (ARDS) 245 272–273 APRV therapy 110–112 barotrauma (See Barotrauma) reduction 245, 246 blast injuries 212 benzodiazepines 165, 276–280 regurgitation 242–243, 247, 266 causes 214 bronchopleural fistula 252–253, 255 remifentanil 276–280 CT assessment 265 cardiovascular effects 271, 272, 277 right ventricular performance 272, delirium in 169 cervical spine damage 245, 243–245 274 dornase alfa 79–80 dental/soft tissue/laryngeal 243 sedation 165–166, 245, 276–280 drugs for 81, 137 dexmedetomidine 166 sleep 276, 277, 278, 279, 349, high tidal volume ventilation in endotracheal intubation 58, 72–73, 348–349, 350, 384 153–154 240, 239–240, 242, 246 sufentanil 276–280 hypoxaemia, PEEP management of extubation, un-planned 249–250 swallowing dysfunction 247, 247 124–125 face/lips/oropharynx 245, 246 tracheal injuries 243, 249, 248–249 inertia/friction issues 347, 333–347 fentanyl 276–280 tracheostomy (See under lung contusions 219 gastrointestinal system 274–276 Tracheostomy) nitric oxide as therapy 139 hypotension/hypoxia 239–242 trauma 43 411 © Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-86781-8 - Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More information Index Adverse effects/complications (cont.) oxygenation of, surface area in 122, AQMS (acute quadriplegic myopathy VAP (See Ventilator-associated 121–122 syndrome) 177 pneumonia (VAP)) pressure mechanics 5, 4–5, 9–11, 268 ARDS. See Acute respiratory distress venous return 271–272, 273 recruitment syndrome (ARDS) VIDD (See Ventilator-induced in lung elastance 346, 345–346 ARDSnet trials diaphragmatic damage (VIDD)) in muscle contraction 353 lung injury, ventilator-associated withdrawals 278, 276–278, 280 surfactant dysfunction 267, 265–267 263–265 Aerial transport issues in low PO2 13 surfactant in 6, 4–6, 9, 267 NMBA usage 171 Aeromedical transportation issues 290, V/˙ Q˙ ratios 15, 120–121, 136, PEEP 124, 125, 146, 216, 267–269 294, 293–294, 295 133–136, 139 permissive hypercapnia 153, 154, Aerosol drug delivery ventilation inequality in low PO2 155 factors affecting 85 15–16, 17 ventilation modes 215 metered dose inhalers 83, 84 wall stress, inspiration and 266 ARF. See Acute respiratory failure (ARF) method selection 83 Amikacin 81, 256–257 Arginine 190 nebulizers (See Nebulizers) Aminoglycosides 256–257 Aripiprazole 170–171 overview 81, 80–81, 82 Aminophylline 201, 360 Arterial blood gas measurement 29–30 AIDS 359–360 Aminosteroid NMBA agents 174, Arterial oxygen content, calculating 119 Airway collapse, risk factors 1–4 175–176 Artificial airway management, lower Airway development, upper 297 Anaesthesia, history of active HMEFs 74 Airway obstruction pneumothorax 392–394 aerosol drug delivery 80–83 children 298, 306 sealed airway 390–392 complications 72–73 (See also Heliox 232 Anaesthetic ventilator modes 88–90 Adverse effects/complications) hypotension/circulatory collapse Analgesia HMEFs 74, 75 205–206 acetaminophen 180 hot water humidifiers 74–75 management 311, 363, 362–363, 364 adverse effects 276–280 humidification 74 pathophysiology 197, 196–197, 198, as delirium risk factor 168–169 mucoactive agents 78–80 363 monitoring 178 overview 72–73 pneumothorax 206–207 NSAIDs 180, 181 tracheobronchial suctioning 75–78 problems associated with 196, 203 opioid agonists 168–169, 179, tube exchange 83 tracheostomy 78, 311, 312, 319 178–179, 180 tubing, monitoring 83–85 tracheostomy/tracheobronchial overview 178 Artificial airway management, upper suctioning 78 Anatomical dead space defined breathing system care Airway patency 363, 362–363, 364 143–145 cuff deflation 71 Airway pressure, increasing 122, 123 Androgens 359–360 cuff inflators, manual 70 Airway pressure release ventilation Antadir 376–377 cuff pressure control 71, 69–71 (APRV) Anti-cholinergic drugs oral hygiene 72 applications of 122, 123 asthma/COPD 200 securing, of tube 69, 67–69 described 110–112, 113 mucus production, decreasing 80 sub-glottic secretion drainage 72, inspiratory time prolongation by primary post-ventilation apnoea 71–72, 262 126–127 334–336 Combitube 56, 57 Airway protection 364, 365 Anti-depressants 348–350 complications 58, 62–63, 72–73 (See Airway resistance, in infants/children Anti-fibrinolytics 137 also Adverse 298–299 Anti-pyretics 148 effects/complications) Alfentanyl 62–63 Antibiotic resistance 261 cricoid pressure application ALI. See Acute lung injury (ALI) Anticholinesterases 334–336 technique 63 Almitrine bismesylate, for V/˙ Q˙ Antimuscarinics 81 drugs/venous access 62–63 mismatch 137 Antipsychotics 170–171 endotracheal tubes (See Alternative recruitment hypothesis 254 Anxiety 349, 348–349, 350 Endotracheal intubation) Alveolar-arterial difference calculation APACHE II model, hyperoxia 270, 271 equipment 59, 60–61 116–119 Apnoea indications 58 Alveolar dead space defined 143–145 in infants/children 299–300 LMAs 56, 57 Alveolar shunts in low PO2 14–15 primary post-ventilation 336, monitoring 59 Alveoli 334–336 nasopharyngeal airways 55, 56 development of 296–297 secondary 340, 339–340 oropharyngeal airways (See diffuse haemorrhage 137, 137, 139 ventilation 106 Oropharyngeal airways) functional anatomy 3, 4 Aprotinin 137 overview 54, 55 minute volume increase/pH 350, APRV. See Airway pressure release oxygenation 58–59, 60, 61, 62 350, 351 ventilation (APRV) placement 57–58 412 © Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-86781-8 - Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More information Index suction apparatus 61–62 standard therapy 199–200 Bjørneboe, Mogens 397–401 tilting bed/trolley 61 metabolic acidosis/hypercapnia in Blast injuries tube cutting technique 66 155–156 barotrauma 213, 216–217 ventilator 63 muscle fatigue and 24–25 bronchopleural fistula 213 Artificial lungs 227–228 pneumothorax 206–207 classification 213 Aspiration Astrup, Poul 397–401 clinical presentation 212, 213–214 as adverse effect 242–243, 247 ATC (automatic tube compensation) diagnosis 211–212 foreign body, in infants/children 297 114 explosions, physics of 210 gastric residual volumes and 188–189 Atelectasis 23–24 incidence 212–213 lung transplantation 224–225 Atracurium outcomes 217 meconium aspiration syndrome 81, AQMS and 177 primary described 210–211, 213 303–304 overview 174–175 quaternary described 211 pulmonary, risk factors 242 properties 175 radiographic findings 213 tidal volume and 266 study data 174 secondary described 211 transportation issues 287 Auer, J. 393 sucking chest wounds 213 VAP transmission via 257, 258–261 Augmented diffusion 305–306 systemic effects of 217 Aspiration pneumonitis 242–243, 245 Automatic tube compensation (ATC) tertiary described 211 Assessment, of need 114 treatment arterial blood gases 29–30 Automode® 113 ECMO 217 availability principle 22 Availability principle 22 fluid administration 217 clinical 23, 29, 25–29, 30, 144 overview 214 diaphragmatic function 27 β-blockers 348–350 PIP/permissive hypercapnia hypercapnia 22–25, 26 Barometric pressure issues in low PO2 216–217 lung volume measurement 27 13 ventilatory strategy, long-term 214 maximal inspiratory pressure 27 Barotrauma Blast waves 210 neurological disorders 30 blast injuries 213, 216–217 Blast wind 210 overview 21 causes 253 Blast zone anatomy 211 patient categories 22–25 clinical presentation 250, 251 Blease, John 395, 394–395 pulse oximetry 28, 27–28, 29 permissive hypercapnia and 154 Blease Pulmoflator 394–395 quality/length of life
Recommended publications
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew Et Al
    US009314465B2 (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew et al. (45) Date of Patent: *Apr. 19, 2016 (54) DRUG COMBINATIONS AND USES IN 2008.0003280 A1 1/2008 Levine et al. ................. 424/456 TREATING A COUGHING CONDITION 2008/O176955 A1 7/2008 Hecket al. 2008, 0220078 A1 9, 2008 Morton et al. (71) Applicant: Infirst Healthcare Limited 2009, O136427 A1 5/2009 Croft et al. 2009, O220594 A1 9, 2009 Field (72) Inventors: John Brew, London (GB); Robin Mark 2012/O128738 A1 5, 2012 Brew et al. Bannister, London (GB) 2012fO252824 A1 10/2012 Brew et al. (73) Assignee: Infirst Healthcare Limited, London FOREIGN PATENT DOCUMENTS (GB) CN 1593451 3, 2005 CN 101024.014 A 8, 2007 (*) Notice: Subject to any disclaimer, the term of this CN 101112383 B 5, 2010 patent is extended or adjusted under 35 DE 4420708 A1 12, 1995 U.S.C. 154(b) by 0 days. EP 2050435 B1 4/2009 GB 2114001 A 8, 1983 This patent is Subject to a terminal dis GB 2284761 A 6, 1995 claimer. GB 2424.185 B 9, 2006 GB 2442828 A 4/2008 JP 62-249924 A 10, 1987 (21) Appl. No.: 14/287,014 JP H1O-316568 A 12/1998 JP 2001-518928 A 10, 2001 (22) Filed: May 24, 2014 JP 200219.3839. A T 2002 JP 2003-012514 A 1, 2003 (65) Prior Publication Data JP 20030552.58 A 2, 2003 JP 2003128549 A 5, 2003 US 2014/O256750 A1 Sep. 11, 2014 JP 2003-321357 A 11, 2003 JP 2005-516917 A 6, 2005 JP 2008O31146 A 2, 2008 Related U.S.
    [Show full text]
  • Automation List – 1St December 2011
    st Automation List – 1 December 2011 Abidec Drops Packsize 25 Adcal D3 Chewable Tabs Packsize 56 Abilify Tabs 10 Mg Packsize 28 Adcal D3 Chewable Tabs Packsize 56 Abstral Tabs 100 Micrograms Packsize 10 Adcal D3 Dissolve Effervescent Tabs Packsize 56 Abstral Tabs 100 Micrograms Packsize 30 Adcal D3 Tabs Packsize 112 Abstral Tabs 200 Micrograms Packsize 10 Adefovir Dipivoxil Tabs 10 Mg Packsize 30 Abstral Tabs 200 Micrograms Packsize 30 Adenuric Tabs 80 Mg Packsize 28 Abstral Tabs 300 Micrograms Packsize 10 Adipine 10 Mr 10 Mg Tabs Packsize 56 Abstral Tabs 300 Micrograms Packsize 30 Adipine 20 Mr 20 Mg Tabs Packsize 56 Abstral Tabs 400 Micrograms Packsize 10 Adipine 30 Xl Tabs 30 Mg Packsize 28 Abstral Tabs 400 Micrograms Packsize 30 Adipine 60 Xl Tabs 60 Mg Packsize 28 Abstral Tabs 600 Micrograms Packsize 30 Adizem Sr 120 Mg Caps Packsize 56 Acamprosate Calcium 333 Mg Ec Tabs Packsize 168 Adizem Sr 180 Mg Caps Packsize 56 Acarbose Tabs 100 Mg Packsize 90 Adizem Sr 90 Mg Caps Packsize 56 Acarbose Tabs 50 Mg Packsize 90 Adizem Sr Tabs 120 Mg Packsize 56 Accolate Tabs 20 Mg Packsize 56 Adizem Xl 120 Mg Caps Packsize 28 Accupro Tabs 10 Mg Packsize 28 Adizem Xl 180 Mg Caps Packsize 28 Accupro Tabs 20 Mg Packsize 28 Adizem Xl 200 Mg Caps Packsize 28 Accupro Tabs 40 Mg Packsize 28 Adizem Xl 240 Mg Caps Packsize 28 Accupro Tabs 5 Mg Packsize 28 Adizem Xl 300 Mg Caps Packsize 28 Accuretic Tabs Packsize 28 Adoport Caps 1 Mg Packsize 100 Acebutolol Caps 100 Mg Packsize 84 Adoport Caps 1 Mg Packsize 50 Acebutolol Caps 200 Mg Packsize 56 Adoport Caps
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug
    USOO544607OA United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug. 29, 1995 54 COMPOST ONS AND METHODS FOR 4,659,714 4/1987 Watt-Smith ......................... 514/260 TOPCAL ADMNSTRATION OF 4,675,009 6/1987 Hymes .......... ... 604/304 PHARMACEUTICALLY ACTIVE AGENTS 4,695,465 9/1987 Kigasawa .............................. 424/19 4,748,022 5/1988 Busciglio. ... 424/195 75 Inventor: Juan A. Mantelle, Miami, Fla. 4,765,983 8/1988 Takayanagi. ... 424/434 4,789,667 12/1988 Makino ............ ... 514/16 73) Assignee: Nover Pharmaceuticals, Inc., Miami, 4,867,970 9/1989 Newsham et al. ... 424/435 Fla. 4,888,354 12/1989 Chang .............. ... 514/424 4,894,232 1/1990 Reul ............. ... 424/439 * Notice: The portion of the term of this patent 4,900,552 2/1990 Sanvordeker .... ... 424/422 subsequent to Aug. 10, 2010 has been 4,900,554 2/1990 Yanagibashi. ... 424/448 disclaimed. 4,937,078 6/1990 Mezei........... ... 424/450 Appl. No.: 112,330 4,940,587 7/1990 Jenkins ..... ... 424/480 21 4,981,875 l/1991 Leusner ... ... 514/774 22 Filed: Aug. 27, 1993 5,023,082 6/1991 Friedman . ... 424/426 5,234,957 8/1993 Mantelle ........................... 514/772.6 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 63 Continuation-in-part of PCT/US92/01730, Feb. 27, 0002425 6/1979 European Pat. Off. 1992, which is a continuation-in-part of Ser. No. 0139127 5/1985 European Pat. Off. 813,196, Dec. 23, 1991, Pat. No. 5,234,957, which is a 0159168 10/1985 European Pat.
    [Show full text]
  • Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine 2013
    Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine, Pyrimidine, Azaindole, Quinoline, Thiazole, Isatin, Phenanthrene, Thiophene We declare that some of the listed products might be protected by valid patents. They are only for scientific research and development purpose. They are not offered for sales in countries where the sales of such products constitutes patents infringement. The liability for patents checking and patents infringement is exclusive at buyers risk! I2CNS LLC CANNOT BE HELD LIABLE FOR ANY VIOLATIONS OF PATENT RIGHTS CAUSED BY CUSTOMERS. CAS No. Product Name and Description 26988-72-7 1-METHYL-DL-TRYPTOPHAN 68886-07-7 2-Fluoro-4-hydroxyphenylaceticacid 72607-53-5 N-(3-AMINOPROPYL)METHACRYLAMIDE 171049-41-5 7-AMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLICACIDTERT- BUTYLESTER 885280-38-6 (3-OXO-CYCLOHEXYL)-CARBAMICACIDTERT-BUTYLESTER 186826-86-8 MOXIFLOXACIN HCL 102735-53-5 L-CYCLOPROPYLALANINE 145100-50-1 2-[N,N-BIS(TRIFLUOROMETHYLSULFONYL)AMINO]PYRIDINE 143491-57-0 Emtricitabine 39809-25-1 2-Amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one 147127-20-6 Tenofovir 716-39-2 2,3-NAPHTHALENEDICARBOXYLICANHYDRIDE 4333-62-4 1,3-DIMETHYLIMIDAZOLIUMIODIDE 108-45-2 m-Phenylenediamine 1961-72-4 R-(3)-HYDROXYMYRISTICACID 131-48-6 N-Acetylneuraminicacid 88196-70-7 (R)-1-(3-Methoxyphenyl)ethylamine 680-31-9 Hexamethylphosphoramide 486-66-8 Daidzein 872-50-4 1-Methyl-2-pyrrolidinone 425378-68-3 2-FLUORO-5-NITROPHENYLBORONICACIDPINACOLESTER 115651-29-1 5-ACETYL-2-AMINO-4-HYDROXYBENZOICACID 115269-99-3 N,N-BIS-BOC-N-ALLYLAMINE
    [Show full text]
  • Pharmaceutical Compoundingand Dispensing, Second
    Pharmaceutical Compounding and Dispensing Pharmaceutical Compounding and Dispensing SECOND EDITION John F Marriott BSc, PhD, MRPharmS, FHEA Professor of Clinical Pharmacy Aston University School of Pharmacy, UK Keith A Wilson BSc, PhD, FRPharmS Head of School Aston University School of Pharmacy, UK Christopher A Langley BSc, PhD, MRPharmS, MRSC, FHEA Senior Lecturer in Pharmacy Practice Aston University School of Pharmacy, UK Dawn Belcher BPharm, MRPharmS, FHEA Teaching Fellow, Pharmacy Practice Aston University School of Pharmacy, UK Published by the Pharmaceutical Press 1 Lambeth High Street, London SE1 7JN, UK 1559 St Paul Avenue, Gurnee, IL 60031, USA Ó Pharmaceutical Press 2010 is a trade mark of Pharmaceutical Press Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society of Great Britain First edition published 2006 Second edition published 2010 Typeset by Thomson Digital, Noida, India Printed in Great Britain by TJ International, Padstow, Cornwall ISBN 978 0 85369 912 5 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The right of John F Marriott, Keith A Wilson, Christopher A Langley and Dawn Belcher to be identified as the author of this work has been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • European Patent Office
    Europäisches Patentamt *EP001021204B1* (19) European Patent Office Office européen des brevets (11) EP 1 021 204 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 47/32, A61L 25/00 of the grant of the patent: 28.12.2005 Bulletin 2005/52 (86) International application number: PCT/US1998/020091 (21) Application number: 98949505.6 (87) International publication number: (22) Date of filing: 25.09.1998 WO 1999/015210 (01.04.1999 Gazette 1999/13) (54) BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS BIOLOGISCHE KLEBER UND VERFAHREN ZUR TOPISCHEN VERABREICHUNG VON WIRKSTOFFEN COMPOSITIONS BIOADHESIVES ET METHODES D’ADMINISTRATION LOCALE D’AGENTS ACTIFS (84) Designated Contracting States: • HOUZE, David AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Miami, FL 33186 (US) MC NL PT SE • KANIOS, David Miami, FL 33196 (US) (30) Priority: 26.09.1997 US 61155 P (74) Representative: Isenbruck, Günter (43) Date of publication of application: Isenbruck, Bösl, Hörschler, Wichmann, Huhn 26.07.2000 Bulletin 2000/30 Patentanwälte Theodor-Heuss-Anlage 12 (73) Proprietor: NOVEN PHARMACEUTICALS, INC. 68165 Mannheim (DE) Miami, FL 33186 (US) (56) References cited: (72) Inventors: FR-A- 2 532 546 GB-A- 1 050 070 • MANTELLE, Juan GB-A- 2 046 773 US-A- 4 593 053 Miami, FL 33176 (US) US-A- 5 656 286 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Electronic Supplementary Material
    Supplementary material Thorax Electronic Supplementary Material Contents: MEDLINE search strategy: ........................................................................................................ 1 Number of search results according to data source: .................................................................. 4 Inclusion/Exclusion criteria of eligible trials: ............................................................................ 5 List of excluded studies after full text review: ......................................................................... 14 Reporting of adverse events and development of other pathologies: ...................................... 19 Deviations between this review and protocol: ......................................................................... 20 Funnel Plots: ............................................................................................................................ 20 Explanation for observed Risk of Bias differences for included trials between this review and Tarrant 2019 review: ................................................................................................................ 24 MEDLINE search strategy: Search was adapted appropriately for other databases. Condition: 1. Acute hypoxic respiratory failure 2. Acute hypoxemic respiratory failure 3. Acute hypoxaemic respiratory failure 4. Acute hypercapnic respiratory failure 5. AHRF 6. Respiratory Distress Syndrome, Adult/ 7. Acute respiratory failure 8. ARF 9. Severe hypoxic respiratory failure 10. Severe
    [Show full text]
  • Wo 2009/015286 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 29 January 2009 (29.01.2009) WO 2009/015286 A2 (51) International Patent Classification: Not classified AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (21) International Application Number: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, PCT/US2008/071055 IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, (22) International Filing Date: 24 July 2008 (24.07.2008) MX, MY,MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TJ, (25) Filing Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 60/961,872 24 July 2007 (24.07.2007) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (71) Applicant (for all designated States except US): NEXBIO, European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, INC. [US/US]; 10665 Sorrento Valley Road, San Diego, California 92121 (US). FR, GB, GR, HR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, (72) Inventors; and CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
    [Show full text]